Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheng-Xin Li

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban|December 23, 2017
Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up studyFang Xie, Rui Wang, Zi-Gang Zhao, et al.
Cellular Microbiology|August 24, 2006
Host defence against C. albicans infections in IgH transgenic mice with V(H) derived from a natural anti-keratin antibodyWei Li, Meng Fu, Jin-Gang An, et al.
Chinese Medical Journal|October 16, 2020
Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasisLin Cai, Jian-Zhong Zhang, Xu Yao, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban|December 23, 2017
Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up studyFang Xie, Rui Wang, Zi-Gang Zhao, et al.
Cellular Microbiology|August 24, 2006
Host defence against C. albicans infections in IgH transgenic mice with V(H) derived from a natural anti-keratin antibodyWei Li, Meng Fu, Jin-Gang An, et al.
Chinese Medical Journal|October 16, 2020
Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasisLin Cai, Jian-Zhong Zhang, Xu Yao, et al.
Pageof 4